Osteopenia and osteoporosis in inflammatory bowel disease;Osteopenia y osteoporosis en la enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 27, Issue 7, 2004, Pages 417-424

  Garcia Planella, Esther ^a   Domenech E ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; CYCLOSPORIN A; ETIDRONIC ACID; FLUORIDE; GLUCOCORTICOID; HEPARIN; VITAMIN D;

ALCOHOL CONSUMPTION; ALGORITHM; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; GENDER; HIGH RISK POPULATION; HUMAN; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SMOKING;

EID: 4544265366     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13064750     Document Type: Review

References (55)

1. Gasche C. Anemia in IBD: the overlooked villain. Inflam Bowel Dis 2000;6:142-50.
2. Vleggaar FP, Van Buuren HR, Wolfhagen FHJ, Schalm SW, Pols HAP. Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:617-21.
3. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905-13.
4. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation, and lymphocyte development. Immunol Cell Biol 1999;77:188-93.
5. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through Osteoprotegerin ligand. Nature 1999;402:304-9.
6. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin estimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signalling. J Cell Biochem 2002;85:825-36.
7. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al. Leptin inhibits osteoclast generation. J Bone Miner Res 2002;17:200-9.
8. Kanis J, Melton L, Christiansen C, Joston CCJ, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:113-41.
9. Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1895-902.
10. Bregenzer N, Erban P, Albrich H, Schmitz G, Feuerbach S, Schölmerich J, et al. Screening for osteoporosis in patients with inflammatory bowel disease by using urinary N-telopeptides. Eur J Gastroenterol 2002;14:599-605.
11. Pollak RD, Karmely F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastoenterol 2000;95:699-704.
12. Silvennoinen JA, Risteli L, Kartunnen TJ, Risteli J. Increased degradation of type 1 collagen in patients with inflammatory bowel disease. Gut 1997;38:223-8.
13. Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-91.
14. Silvennoinen JA, Kartunnen TJ, Niemela SE, Manalius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-6.
15. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-33.
16. Gosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-9.
17. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000;119:1203-8.
18. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10:250-6.
19. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997;40:313-9.
20. Herzog D, Bishop N, Glorieux F, Seitman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. Infl Bowel Dis 1998;4:261-7.
21. Gokhales R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998;114:902-11.
22. Boot AM, Bouquet J, Krenning EP, de Munick Keizer-Schrama SMPF. Bone mineral density and nutritional status in children with chronic inflamatory bowel disease. Gut 1998;42:188-94.
23. Motley RJ, Crawley EO, Evans C, Rhodes J. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988;29:1332-6.
24. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995;5:156-60.
25. Motley R, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone and Mineral 1993;23:95-104.
26. Clements D, Motley RJ, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-60.
27. Silvennoinen JA. Relationship between vitamin D, parathiroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996;239:131-7.
28. Scharla SH, Minne HW, Lempert UG, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol 1994;102:44-9.
29. Driscoll RHJ, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982;83:1252-8.
30. Compston JE, Creamer B. Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. Gut 1997;18:171-5.
31. Hessov I, Mosekilde L, Melsen F, et al. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastoenterol 1984;19:691-6.
32. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathiroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002;37:192-9.
33. Dinca M, Fries W, Luissetto G, Peccalo F, Bottega F, Leone L, et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999;94,5:1292-7.
34. Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003;98:1797-801.
35. Holgado S, Garcia-Planella E, Mañosa M, Sanmartí M, Valls-Roc M, Domènech E, et al. Bone mass and inflammatory bowel disease. Ann Rheum Dis 2003;62:532.
36. Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002;87:2460-6.
37. Schulte CMS, Dignass AU, Goebell H, Röher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000;119:909-20.
38. Schulte CM, Goebell H, Röher HD, Schulte KM. Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease. Dig Dis Sci 2001;46:2521-8.
39. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA 2002;288:1889-97.
40. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in celiac disease and inflammatory bowel disease. Gut 2000;46(Suppl 1):1-8.
41. AGA Technical Review on Osteoporosis in Gastrointestinal Diseases. Gastroenterology 2003;124:795-841.
42. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
43. Arden NK, Cooper C. Assessment of the risk of fracture in patients with gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:865-8.
44. Vestergaard P, Krogh K, Rejmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-81.
45. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu N. Incidence of fracture among patients with inflammatory bowel disease. A population-based study. Ann Int Med 2000;133:795-9.
46. Loftus EV, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton III J. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002;123:468-75.
47. Stockbrügger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002;16:1519-27.
48. Ginard D, Riera J, Bonet N, Barranco L, Reyes J, Escarda A, et al. Malabsorción de lactosa en la colitis ulcerosa. Estudio de casos y controles. Gastroenterol Hepatol 2003;26:469-74.
49. Domènech E, Rosinach M, Maurer-Pons M, Deselaers A, Garcia-Planella E, Bernal I, et al. Dairy products in acute inflammatory bowel disease: should they be excluded from the diet? Gastroenterology 2002;122(Suppl):A498.
50. Homik J, Suárez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane review). En: The Cochrane Library, Issue 1 Oxford: Update Software, 2002.
51. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Biphosphonates for steroid-induced osteoporosis (Cochrane review). En: The Cochrane Library, Issue 1 Oxford: Update Software, 2002.
52. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suárez-Almazor ME, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis (Cochrane review). En: The Cochrane Library, Issue 1 Oxford: Update Software, 2002.
53. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Aleridronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-46.
54. Abitbol V, Mary JY, Roux C, Soulés JC, Belaiche J, Dupas L, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002;16:919-27.
55. Siffledeen J, Chalmers-Nixon T, Fedorak RN, Siminoski K, Steinhart H. Etidronate plus calcium and vitamin D is equivalent to calcium and vitamin D alone in preventing bone mineral density loss in patients with Crohn's disease. Gastroenterology 2002;122(Suppl):A62.